CDK4 and neoplasm: In addition to protecting lymphocyte populations and increasing immune activation through differential T‐cell recovery, trilaciclib and other CDK4/6 inhibitors have been shown to enhance antitumour responses through other mechanisms in preclinical models, including enhanced T‐cell activation through modulation of nuclear factor of activated T‐cell activity and upregulation and stabilisation of PD‐L1 expression on tumour cells, resulting in increased sensitivity to ICI.18, 20